Research Site

Kasugai-shi 487-0031

3 studies enrolling now · 15 studies all time

What they study most

Chronic Kidney Disease, Chronic Kidney Disease and Hypertension, Coronary Heart Disease (CHD), Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD), Heart Failure, Heart Failure With Preserved Ejection Fraction, Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure and Impaired Kidney Function, Hyperkalemia, IgAN, Immunoglobulin A Nephropathy, Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Studies at this site

• A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure — Recruiting now
• A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM — Recruiting now
• Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function — Recruiting now
• A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure. — Running, not enrolling
• Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
• A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia — Stopped early
• A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2 — Completed
• Study to Evaluate the Efficacy and Safety of AZD4831 in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40% — Completed
• Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction — Completed
• A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease — Stopped early
• Efficacy, Safety and Tolerability of AZD9977 and Dapagliflozin in Participants With Heart Failure and Chronic Kidney Disease — Completed
• Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure. — Completed
• DETERMINE-preserved - Dapagliflozin Effect on Exercise Capacity Using a 6-minute Walk Test in Patients With Heart Failure With Preserved Ejection Fraction — Completed
• Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia — Completed
• Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History — Completed